When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
Zacks.com on MSN21h
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded DealThis week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback